Advertisement
AXON vs INO
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Inovio Pharmaceuticals (INO) Stock Comparison
Key Takeaways
- AXON is a profitable, large-cap public-safety technology leader, while INO is a pre-revenue clinical-stage biotech; the two operate in fundamentally different risk and return profiles.
- AXON has shown resilient fundamentals (roughly 35% revenue growth) but weak recent price momentum, while INO trades near its 52-week low with high volatility tied to a single regulatory decision.
- Analysts rate both stocks "Buy," yet AXON's consensus target implies far more modest upside than INO's, which reflects INO's substantially higher uncertainty and dilution risk.
- AXON's story is driven by recurring software and AI adoption; INO's is concentrated on the FDA review of its lead candidate, INO-3107.
- For more detail, explore AXON Major News and AXON Today's Price Move, along with INO Major News and INO Today's Price Move.
- To see how automated strategies are positioning across these and other tickers, explore Trending AI Robots.
Introduction
Comparing AXON and INO places two very different investment theses side by side. Axon Enterprise sells connected devices and cloud software to law-enforcement and public-safety agencies, while Inovio Pharmaceuticals develops experimental DNA-based medicines with no approved product yet on the market. This stock comparison is most relevant to investors weighing a profitable growth company against a high-risk, event-driven biotech. Growth and momentum traders may focus on AXON's recent product catalysts, whereas speculative and healthcare-oriented investors may track INO's regulatory milestones. Understanding their relative performance and market positioning helps clarify which profile fits a given portfolio.
AXON Overview and Recent Performance
Axon Enterprise (AXON) provides public-safety technology, including TASER devices, body cameras, and a cloud software ecosystem covering digital evidence, records, and AI-enabled tools. The company has built a recurring-revenue model, with annual recurring revenue near $1.6 billion, a net revenue retention rate of about 126%, and roughly $15 billion in future contracted bookings. Revenue has expanded in the mid-30% range year over year, underscoring durable demand.
Despite solid fundamentals, the stock has lagged recently. AXON trades in the low-to-mid $400s, well below its 52-week high near $764, and is down more than 20% year to date. Sentiment has been pressured by valuation concerns and by margin compression as lower-margin hardware and counter-drone offerings scale. Recent weeks have brought a rebound, however, driven by the unveiling of the Axon Body 5 camera, which the company says delivers roughly 25 times the AI processing power of earlier generations. New federal contracts, including body-camera and counter-drone work, have also supported the recovery ahead of third-quarter earnings.
INO Overview and Recent Performance
Inovio Pharmaceuticals (INO) is a clinical-stage biotechnology company developing DNA medicines targeting HPV-related diseases, cancer, and infectious diseases. Its lead candidate, INO-3107, is under review by the U.S. Food and Drug Administration (FDA) as a potential treatment for recurrent respiratory papillomatosis (RRP), a rare condition. The FDA accepted the Biologics License Application (BLA) and assigned a target decision date in late October 2026, though under a standard rather than accelerated review timeline.
INO trades near $1, at the lower end of its 52-week range, and has fallen more than 30% year to date. The stock is highly volatile, with an average weekly move well above the broader market, reflecting concentration of risk around a single regulatory event. The company reported a narrower net loss in recent quarters and expects its cash to fund operations into early 2027, but it has relied on equity raises that have diluted existing shareholders. Sentiment remains closely tied to whether INO-3107 secures approval and to the company's ability to fund commercialization.
Trending AI Robots
Tickeron operates hundreds of AI trading bots that collectively trade thousands of different tickers, each with its own strategy, timeframe, performance statistics, and watchlist. Because not every bot suits every market environment, Tickeron curates a focused selection in its Trending AI Robots section, highlighting only those judged best aligned with current conditions. Bots vary widely, from short-term momentum systems to longer-horizon trend followers, and their track records are tracked through measurable statistics such as trade counts, win rates, and drawdowns. For traders interested in how automated, data-driven strategies are currently positioned across names like AXON and INO, reviewing the Trending AI Robots list can offer a useful, systematic perspective.
Head-to-Head Comparison
The clearest contrast between these two stocks is the stage of their business life cycles. AXON is profitable and growing, with diversified revenue across devices, software, and services, and a moat built on recurring contracts with public agencies. INO generates negligible revenue and remains dependent on capital raises while awaiting a single regulatory outcome.
Growth drivers differ sharply. AXON's upside rests on software attach rates, AI-enabled bundles, and expansion into drones and counter-drone technology. INO's upside is binary, hinging on FDA approval and successful commercial launch of INO-3107. Risk factors likewise diverge: AXON faces valuation and margin concerns alongside exposure to government budgets, while INO faces clinical, regulatory, financing, and dilution risks.
On relative performance, both stocks have declined over the past year, but AXON's pullback occurred from a position of profitability and strong revenue momentum, whereas INO's decline reflects persistent losses and high cash burn. In sector terms, AXON sits in technology and aerospace/defense-adjacent markets, while INO is a healthcare and biotech name with event-driven price behavior.
Tickeron AI Verdict
Based on observable trend consistency, stability, and catalyst structure, Tickeron's AI would likely favor AXON over INO in the current environment. AXON combines sustained revenue growth, a recurring-revenue base, and a recent technical rebound supported by product and contract catalysts, which together suggest a more consistent trend profile. INO's outlook, by contrast, is concentrated in a single binary FDA decision and carries elevated volatility and financing uncertainty. While INO may offer larger potential upside if its lead candidate is approved, its risk-adjusted positioning appears weaker. This assessment reflects a probabilistic read of current data rather than a definitive prediction, and market conditions can shift quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and INO is a Hold.
AXON in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 28 of 33 cases where AXON's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 273 of 370 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 31 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 80 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock worse than average.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).
INO in downward trend: price expected to drop as it breaks its higher Bollinger Band on November 02, 2026
INO broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 33 similar instances where the stock broke above the upper band. In 29 of the 33 cases the stock fell afterwards. This puts the odds of success at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for INO moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 47 cases where INO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for INO entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on INO as a result. In 56 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for INO just turned positive on November 02, 2026. Looking at past instances where INO's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
INO moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for INO crossed bullishly above the 50-day moving average on November 06, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +6.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where INO advanced for three days, in 185 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. INO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (28.741) is normal, around the industry mean (3.498). P/E Ratio (-1.180) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1000.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
AXON | INO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 92 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 90 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 82 | 100 | |
SMR RATING 1..100 | 81 | 100 | |
PRICE GROWTH RATING 1..100 | 65 | 36 | |
P/E GROWTH RATING 1..100 | 80 | 60 | |
SEASONALITY SCORE 1..100 | 43 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (90) in the Biotechnology industry is in the same range as INO (90) in the Medical Specialties industry. This means that AXON’s stock grew similarly to INO’s over the last 12 months.
AXON's Profit vs Risk Rating (82) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that AXON’s stock grew similarly to INO’s over the last 12 months.
AXON's SMR Rating (81) in the Biotechnology industry is in the same range as INO (100) in the Medical Specialties industry. This means that AXON’s stock grew similarly to INO’s over the last 12 months.
INO's Price Growth Rating (36) in the Medical Specialties industry is in the same range as AXON (65) in the Biotechnology industry. This means that INO’s stock grew similarly to AXON’s over the last 12 months.
INO's P/E Growth Rating (60) in the Medical Specialties industry is in the same range as AXON (80) in the Biotechnology industry. This means that INO’s stock grew similarly to AXON’s over the last 12 months.
| AXON | INO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 85% |
| Stochastic ODDS (%) | 1 day ago 84% | 1 day ago 81% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 79% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 75% |
| TrendWeek ODDS (%) | 1 day ago 69% | 1 day ago 87% |
| TrendMonth ODDS (%) | 1 day ago 71% | 1 day ago 76% |
| Advances ODDS (%) | 16 days ago 74% | 15 days ago 79% |
| Declines ODDS (%) | 2 days ago 70% | 6 days ago 88% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 88% |
| Aroon ODDS (%) | 1 day ago 82% | 1 day ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green while INO’s FA Score has 0 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- INO’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while INO’s TA Score has 5 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 5 bearish.
- INO’s TA Score: 5 bullish, 5 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -25.64% price change this week, while INO (@Biotechnology) price change was -12.65% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was +5.08%. For the same industry, the average monthly price growth was -0.97%, and the average quarterly price growth was -12.77%.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
AXON is expected to report earnings on Mar 02, 2027.
INO is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Aerospace & Defense (+5.08% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
INO and
Correlation & Price change
A.I.dvisor indicates that over the last year, INO has been loosely correlated with AXON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To INO | 1D Price Change % | ||
|---|---|---|---|---|
| INO | 100% | +1.72% | ||
| AXON - INO | 53% Loosely correlated | +4.26% | ||
| ARRY - INO | 52% Loosely correlated | +9.94% | ||
| LPCN - INO | 41% Loosely correlated | N/A | ||
| AMRN - INO | 39% Loosely correlated | -0.34% | ||
| PCSA - INO | 38% Loosely correlated | N/A | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DRMP | 15.52 | 1.26 | +8.80% |
| Tuttle Capital Memory Stack Income Blast ETF (DRMP) | |||
| EVIM | 52.30 | 0.06 | +0.11% |
| Eaton Vance Intermediate Municipal Income ETF (EVIM) | |||
| APRZ | 39.72 | N/A | N/A |
| TrueShares Structured Outcome (April) ETF (APRZ) | |||
| EPP | 55.97 | -0.02 | -0.04% |
| iShares MSCI Pacific ex-Japan ETF (EPP) | |||
| NMI | 9.59 | -0.02 | -0.19% |
| Nuveen Municipal Income | |||